Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr 7;20(13):3475-84.
doi: 10.3748/wjg.v20.i13.3475.

Therapeutic drug monitoring in patients with inflammatory bowel disease

Andres J Yarur  1 , Maria T Abreu  1 , Amar R Deshpande  1 , David H Kerman  1 , Daniel A Sussman  1
Affiliations
Review

Therapeutic drug monitoring in patients with inflammatory bowel disease

Andres J Yarur et al. World J Gastroenterol. .

Abstract

Thiopurine analogs and anti-tumor necrosis factor (TNF) agents have dramatically changed the therapeutics of inflammatory bowel diseases (IBD), improving short and long-term outcomes. Unfortunately some patients do not respond to therapy and others lose response over time. The pharmacokinetic properties of these drugs are complex, with high inter-patient variability. Thiopurine analogs are metabolized through a series of pathways, which vary according to the patients' pharmacogenetic profile. This profile largely determines the ratios of metabolites, which are in turn associated with likelihoods of clinical efficacy and/or toxicity. Understanding these mechanisms allows for manipulation of drug dose, aiming to reduce the development of toxicity while improving the efficacy of treatment. The efficacy of anti-TNF drugs is influenced by many pharmacodynamic variables. Several factors may alter drug clearance, including the concomitant use of immunomodulators (thiopurine analogs and methotrexate), systemic inflammation, the presence of anti-drug antibodies, and body mass. The treatment of IBD has evolved with the understanding of the pharmacologic profiles of immunomodulating and TNF-inhibiting medications, with good evidence for improvement in patient outcomes observed when measuring metabolic pathway indices. The role of routine measurement of metabolite/drug levels and antibodies warrants further prospective studies as we enter the era of personalized IBD care.

Keywords: Adalimumab; Anti-tumor necrosis factor; Antibodies; Azathioprine; Drug level; Drug monitoring; Inflammatory bowel disease; Infliximab; Thioguanine; Thiopurines.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Metabolic pathway of azathioprine/mercaptopurine metabolism. AZA: Azathioprine; MP: Mercaptopurine; TPMT: Thiopurine methyltransferase; XO: Xanthine oxidase; IMPDH: Inosine-5-monophosphate dehydrogenase; GMPS: Guanidine- 5-monophosphate synthetase; 6-TA: 6-Thiouric acid; 6-MMP: 6-Methyl- mercaptopurine; 6-TIMP, 6-Thioinosine monophosphate; 6-MeTIMP: 6-Methylthioinosine monophosphate; 6-MeTITP: 6-Methyl thioinosine triphosphate pyrophosphate; 6-TITP: 6-Thioinosine triphos- phate pyrophosphate; TXMP: Thioxanthosine monophosphate; 6-TGN: 6-Thioguanine nucleotides; 6-TGMP: 6-Thioguanine monophosphate; 6-TGDP: 6-Thioguanine diphosphate; 6-TGTP: 6-Thioguanine triphosphate.
Figure 2
Figure 2
Algorithm with recommendation on how to manage patients that fail therapy with Azathioprine/Mercaptopurine. AZA: Azathioprine; MP: Mercaptopurine; 6-TGN: 6-Thioguanine nucleotides; 6-MMP: 6-Methyl-mercaptopurine.
Figure 3
Figure 3
Variables associated with Anti-tumor necrosis factor levels. TNF: Tumor necrosis factor.
Figure 4
Figure 4
Approaches to patients on infliximab in the setting of lose of response. ATI: Anti-infliximab antibody; IFX: Infliximab; TNF: Tumor necrosis factor.
See this image and copyright information in PMC

References

    1. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:661–673. - PubMed
    1. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65. - PubMed
    1. Thomas CW, Myhre GM, Tschumper R, Sreekumar R, Jelinek D, McKean DJ, Lipsky JJ, Sandborn WJ, Egan LJ. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther. 2005;312:537–545. - PubMed
    1. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol. 2005;20:1149–1157. - PubMed
    1. Kröplin T, Iven H. Methylation of 6-mercaptopurine and 6-thioguanine by thiopurine S-methyltransferase. A comparison of activity in red blood cell samples of 199 blood donors. Eur J Clin Pharmacol. 2000;56:343–345. - PubMed

MeSH terms

LinkOut - more resources